RxDoctor Payments Data

Alfred Shtainer, MD

Urology · New York, NYNPI 1952328718

Payments from drug & device makers

$520in general payments, 2019–2025

Across 24 payments — averaging $21.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$210
  • Endo USA, Inc.$125
  • Pfizer$54
  • Endo Pharmaceuticals Inc.$51
  • Boston Scientific$38
  • Amarin Pharma, Inc.$21
  • plus $20 from 1 others

What the payments were for

  • Food & beverage$50697%
  • Education$143%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$520 in reported general payments places this provider in the 25th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$444,423
Medicare patients
354
Services billed
7,007

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron144$74,313
Tamsulosin Hcl846$8,723
Finasteride339$2,919
Oxybutynin Chloride ErOxybutynin Chloride107$1,639
Dutasteride81$1,512
Potassium Citrate ErPotassium Citrate20$1,379
Alfuzosin Hcl ErAlfuzosin Hcl72$1,340
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst67$725
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav105$602
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip21$434
Fluconazole56$326
Doxazosin Mesylate15$152
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim58$140
Ciprofloxacin Hcl18$90
Doxycycline Hyclate14$60

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$210$74,313144 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 952 urology providers in New York.

Other urology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →